Institute for International Research

You can purchase the conference documentation for Targeting Metabolic Disorders for only $399 (plus shipping & handling). Contact Customer Service at 800.390.4078 or reg@ibcusa.com for assistance.

---

The TZDs: Lessons Learned in Metabolic and Skeletal Homeostasis
Clifford J. Rosen, M.D., Senior Scientist, St. Joseph Hospital, Member, FDA Endocrine Advisory Board

Do Insulin Sensitizers Have a Future?
Michael Cawthorne, Ph.D., Director of Metabolic Research, Clore Laboratory, University of Buckingham, United Kingdom

The CETP Target - Challenges and Future Progress
Carl Sparrow, Ph.D., Director, Lipid Biochemistry, Merck Research Laboratories

Structure-Activity Relationship of 5,6-Diaryl-pyrazine-2-amides, A Novel Class of CB1 Receptor Antagonists
Leifeng Cheng, Ph.D., Principal Scientist, Medicinal Chemistry, AstraZeneca R&D, Sweden

Resolving Side Effect Problems with PPAR Targets: Case Study of Chiglitazar, A Configuration-Restricted PPAR Pan-Agonist for T2D Now in Human Trials
Xian-Ping Lu, Ph.D., President, and Chief Scientific Officer, Shenzhen Chipscreen Biosciences, Inc., China

CRx-401, a Novel Insulin Sensitizer Discovered Using a Systems Biology Approach
Margaret S. Lee, Ph.D., Executive Director, Therapeutic Area Research, CombinatoRx, Incorporated

Metformin as a Platform for Combination Drug Therapy of Metabolic Diseases
Carl A. Pelzel, President and Chief Executive Officer, Depomed, Inc.

Strategies for the Discovery of Anti-Obesity Drugs: Balancing Risk with Hope
Jon Arch, Ph.D., Deputy Director of Metabolic Research, Clore Laboratory, University of Buckingham, United Kingdom

Targets Affecting Lipid Metabolism as Potential Treatments for Obesity and its Complications
Karin Conde-Knape, Ph.D., Research Leader, Metabolic and Vascular Diseases, Roche

Ghrelin Receptor Antagonists: Therapeutic Value for Obesity and Diabetes
William P. Esler, Ph.D., Principal Research Scientist, Diabetes Translational Pharmacology, Cardiovascular, Metabolic and Endocrine Disorders, Global Research & Development, Pfizer Inc.

From Discovery to the Clinic with XOMA 052: A Novel Anti-IL1β Antibody
Alan M. Solinger, M.D., FACP FACR, Vice President, Clinical Immunology, XOMA (US) LLC

Role of Inflammation in Insulin Resistance and Diabetic Heart
Jason K. Kim, Ph.D., Associate Professor, Department of Cellular & Molecular Physiology, Pennsylvania State University College of Medicine

Mechanisms of SIRT1 Activation for Treating Diabetes
Philip D. Lambert Ph.D., Senior Director, Pharmacology, Sirtris Pharmaceuticals

From Selective PPAR Ligands to PPAR Pan-agonists
Stephen W. Rafferty, Ph.D., Principal Scientist, MDR Exploratory Chemistry, GlaxoSmithKline

A Synthetic Adrenal Androstene with Glucose Lowering and Insulin Sensitizing Properties
Jaime Flores-Riveros, Ph.D., Vice President, Endocrinology & Metabolism, Hollis-Eden Pharmaceuticals, Inc.

Comprehensive Metabolic Analysis for Understanding of Chronic Disease Mechanisms
Christopher B. Newgard, Ph.D., Director, Sarah W. Stedman Nutrition and Metabolism Center, W. David and Sarah W. Stedman Distinguished Professor, Duke University Medical Center

Mitochondrial Function and Insulin Action in Skeletal Muscle
Deborah M. Muoio, Ph.D., Assistant Professor, Medicine and Pharmacology & Cancer Biology, Duke University Medical Center

Regulation of the MAPK Signaling Network
Gary L. Johnson, Ph.D., Professor & Chairman, Department of Pharmacology, University of North Carolina

Cardiac Dysfunction in Prediabetic Metabolic Syndrome; Is JTV519 (K201) Future Therapy?
U. Deniz Dincer, M.D., Ph.D., Assistant Research Professor, Cellular & Integrative Physiology, Indiana University School of Medicine

Role of Vasodilating Beta-Adrenoceptor Blockers
Keshore R.Bidasee, Ph.D., Associate Professor, Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center

MR Technology to Quantify Body Composition
Derek Nunez, M.A., M.D., FRCP, Director, Metabolic Experimental Medicine, GlaxoSmithKline

Imaging of Beta Cell Mass
Lars Johansson, Ph.D., Senior Research Scientist, Discovery Medicine, AstraZeneca R&D, Sweden